Figure 3: Early Pharmacological CCR2 Antagonism After TAC Blunts Late Cardiac Remodeling
2019-06-11T07:07:57Z (GMT) by
(A) Experimental protocol for treatment with the CCR2 antagonist RS-504393 after TAC. HW to TL ratios (B) and cardiomyocyte area measured using wheat germ agglutinin staining (C) in mice treated with CCR2 antagonist or vehicle 4 weeks after TAC or sham operation. (D) LV gene expression of hypertrophic markers atrial and B-type natriuretic peptide (ANP and BNP, respectively) from the same experimental groups. Statistical comparisons for ANP expression were performed after logarithmic data transformation as described in text. (E) Representative Masson’s trichrome stains of the LV and fibrosis quantitation for the same groups. Scale bar = 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n = 5 to 7 per group.